title: Multiagent PET for risk characterization in sarcoma.
abstract: A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences.
  
  
  METHODS
  We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with (11)C-thymidine for cellular proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-glycoprotein activity, in comparison with (15)O-water for blood flow and (11)C-CO(2) for metabolite analysis and (18)F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy.
  
  
  RESULTS
  Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified.
  
  
  CONCLUSIONS
  This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.
authors.affiliation: Department of Radiology, University of Washington, Seattle, Washington, USA. jeary@u.washington.edu
authors.forename: Janet F
authors.initials: JF
authors.lastname: Eary
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Link
authors.forename: Mark
authors.initials: M
authors.lastname: Muzi
authors.forename: Ernest U
authors.initials: EU
authors.lastname: Conrad
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
authors.forename: Jedediah K
authors.initials: JK
authors.lastname: White
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Krohn
mesh_terms: D002245:Carbon Dioxide; D005240:Feasibility Studies; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007553:Isotope Labeling; D008920:Misonidazole / Q000031:analogs & derivatives; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals; D018570:Risk Assessment; D012509:Sarcoma / Q000000981:diagnostic imaging*; D013936:Thymidine; D014700:Verapamil
chemical_list: D019275:Radiopharmaceuticals; C031843:fluoromisonidazole; D019788:Fluorodeoxyglucose F18; D002245:Carbon Dioxide; D008920:Misonidazole; D014700:Verapamil; D013936:Thymidine